Digene Corp. v. VENTANA MEDICAL SYSTEMS, INC.

476 F. Supp. 2d 444, 2007 U.S. Dist. LEXIS 15368, 2007 WL 706931
CourtDistrict Court, D. Delaware
DecidedMarch 6, 2007
DocketC.A.01 752 MPT
StatusPublished
Cited by13 cases

This text of 476 F. Supp. 2d 444 (Digene Corp. v. VENTANA MEDICAL SYSTEMS, INC.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Digene Corp. v. VENTANA MEDICAL SYSTEMS, INC., 476 F. Supp. 2d 444, 2007 U.S. Dist. LEXIS 15368, 2007 WL 706931 (D. Del. 2007).

Opinion

MEMORANDUM ORDER

THYNGE, United States Magistrate Judge. ■

Currently before the court is defendant Ventana Medical Systems, Inc.’s (“Venta *445 na”) motion to dismiss Count IV of Digene Corporation’s (“Digene”) Second Amended Complaint (“Count IV”). 1 For the reasons discussed below, Ventana’s motion is granted.

BACKGROUND 2

On November 19, 2001 Digene filed a complaint against Ventana for willful infringement of United States Patent Nos. 4,849,331 (“the ’331 patent”) and 4,849,332 (“the ’332 patent”) in conjunction with the development, manufacture, marketing, sales, and offers for sale of its INFORM® HPV High Risk Probe and in its INFORM® HPV Low Risk Probe Products. 3 Digene further alleged that Ventana willfully induced others to infringe the patents-in-suit. 4 In the initial complaint, Di-gene sought, among other things, damages for Ventana’s past infringement, enhanced damages, and attorneys’ fees for Ventana’s willful infringement, and an injunction against Ventana’s continued infringement. 5 On February 2, 2002, Ventana answered the complaint, denying infringement and raising several defenses, including the affirmative defense that its allegedly infringing activities are licensed under the ’332 patent. 6

On September 23, 2002, Ventana and Beckman Coulter, Inc. (“Beckman”) executed an Asset Purchase Agreement (the “2002 APA”), which provided that Ventana would purchase Beckman’s entire right, title and interest in certain assets, including rights under a 1991 sublicense between Instituí Pasteur (“IP”) and Beckman. 7 On October 18, 2002, Digene moved for leave to file an Amended Complaint, 8 which the court granted on December 10, 2002. 9 On December 13, 2002, Digene filed its Amended Complaint, adding Beckman as a defendant and additional claims, including civil conspiracy. 10 On December 27, 2002, Ventana filed a motion to compel arbitration, to the stay proceedings, and to dismiss the conspiracy claim in the Amended Complaint. 11

On January 28, 2003, Digene moved for leave to file a Second Amended Complaint (“SAC”). 12 Leave was granted by the court, 13 and the SAC was deemed filed on March 5, 2003. 14 Count IV of the SAC asserts a claim for civil conspiracy. 15

On May 7, 2004, the court ordered Di-gene and Beckman to arbitration and stayed this case pending the outcome of *446 that arbitration. 16 Arbitration took place during March 2006 and the arbitration panel issued its award on July 27, 2006. 17 The court lifted the stay of these proceedings on August 15, 2006 18 and on August 29, 2006, Ventana filed its motion to dismiss the civil conspiracy claim, Count IV, of the SAC. 19 '

DISCUSSION

In reviewing a motion to dismiss under Rule 12(b)(6), the court must assume the truth of all well pleaded factual allegations set forth in the complaint, and must construe them in the light most favorable to the non-moving party. 20 “While a court will accept well-plead allegations as true for the purposes of the motion, it will not accept unsupported conclusions, unwarranted inferences, or sweeping legal conclusions cast in the form of factual allegation.” 21

Under Delaware law, civil conspiracy requires: “(1) A confederation or combination of two or more persons; (2) An unlawful act done in furtherance of the conspiracy; and (3) Actual damage.” 22 “Civil conspiracy is not an independent cause of action in Delaware, but requires an underlying wrong which would be actionable absent the conspiracy.” 23

Ventana argues that Count IV must be dismissed. Ventana contends that Digene only pleads two conspiratorial acts as part of the civil conspiracy claim: conspiracy to commit patent infringement; and conspiracy to evade its discovery obligations. Ventana argues that neither of these alleged conspiratorial acts can support Digene’s civil conspiracy claim as a matter of law.

First, Ventana argues that conspiracy to commit patent fraud cannot support Di-gene’s civil conspiracy claim because it is preempted by federal patent law and, therefore, fails to state a viable claim. Second, Ventana argues that alleged evasion of discovery obligations under the Federal Rules of Civil Procedure cannot create a private cause of action and, therefore, likewise fails to state a viable claim.

Digene counters that it “pleaded all the requisite elements of a civil conspiracy claim under Delaware law ... that two actors, Ventana and Beckman, conspired for the unlawful purpose of interfering with Digene’s business opportunities, and that Digene was monetarily injured as a result.” 24 Digene argues that accepting those allegations as true establishes a civil conspiracy claim under Delaware law. Di- *447 gene further argues that, “to the extent Digene’s civil conspiracy claim is based on underlying allegations of patent infringement, it is not clear that such a claim is preempted by federal law.” 25 Digene maintains that “the U.S. Court of Appeals for the Federal Circuit has recognized a claim for civil conspiracy to commit patent infringement.” 26 Finally, Digene contends that Ventana misreads its civil conspiracy count as an attempt to sanction Ventana for discovery abuses. Digene avers that its allegations that Ventana improperly concealed various information “bolsters its conspiracy claim in that it is further evidence of the conspiracy between Ventana and Beckman to hide information regarding the fraudulent Ventana/Beckman transaction from Digene and deprive or at least delay Digene’s ability to challenge that transaction, thereby interfering with Digene’s business opportunities.” 27

In its entirety, Count IV of the SAC recites:

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Williams v. Sontchi
D. Delaware, 2020
Carmax Auto Superstores, Inc. v. Sibley
194 F. Supp. 3d 392 (D. Maryland, 2016)
Grubbs v. University of Delaware Police Department
174 F. Supp. 3d 839 (D. Delaware, 2016)
Conceal City, L.L.C. v. Looper Law Enforcement, LLC
917 F. Supp. 2d 611 (N.D. Texas, 2013)
In Re Gjestvang
405 B.R. 316 (E.D. Arkansas, 2009)
Shahin v. Darling
606 F. Supp. 2d 525 (D. Delaware, 2009)
Good v. Khosrowshahi
296 F. App'x 676 (Tenth Circuit, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
476 F. Supp. 2d 444, 2007 U.S. Dist. LEXIS 15368, 2007 WL 706931, Counsel Stack Legal Research, https://law.counselstack.com/opinion/digene-corp-v-ventana-medical-systems-inc-ded-2007.